Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Developing new treatments for diabetes has emerged as an area of focus for biotechs. GLP-1 agonists in particular are now a major space for research and development among the biggest players in the space. Diabetes is a chronic disease of insulin resistance and/or inability to produce insulin, a hormone essential to metabolism. With over 347 million people in the world afflicted with diabetes type 2 (according to the World Health Organization), drugs in this space have the potential to reach blockbuster status, and companies are consequently clamoring for market share. In particular, GLP-1 (glucagon-like peptide-1) agonists mimic an endogenous incretin hormone that spurs the body to produce more of its own insulin; these agents hold the distinct advantage of being either once-a-day or weekly dosing.
The field is becoming more crowded, with Novo Nordisk's blockbuster Victoza, Bristol-Myers Squibb and AstraZeneca's Byetta and Bydureon, and Sanofi's once-daily Lyxumia.
http://www.dailyfinance.com/2014/02/02/fierce-competition-in-the-diabetes-drug-market/
The field is becoming more crowded, with Novo Nordisk's blockbuster Victoza, Bristol-Myers Squibb and AstraZeneca's Byetta and Bydureon, and Sanofi's once-daily Lyxumia.
http://www.dailyfinance.com/2014/02/02/fierce-competition-in-the-diabetes-drug-market/